Agenda: Day 2

NETWORKING BREAKFAST:
BUILD COMMUNITY CONTACTS

OPENING COMMENTS FROM YOUR HOST

UPDATE FROM CADTH

Keep your Submission Strategy up to Date with the Latest Developments at CADTH

UPDATE FROM INESSS

Discover how INESSS Fits within Quebec’s Revised Life Sciences Strategy, its Impact on HTA in Canada and Market Access

KEYNOTE ADDRESS: NATIONAL STRATEGY FOR DRUGS FOR RARE DISEASES

Align your Market Access Plans with National Strategy Advances for Drugs for Rare Diseases

ROUNDTABLES → DISCOVER THOUGHT-PROVOKING IDEAS

KEYNOTE PANEL: MEETING FUTURE CHALLENGES

Is Canada Ready for the New Wave of Treatments?

PANEL DISCUSSION: THE EVOLUTION OF PATIENT SUPPORT PROGRAMS

Clarify your Market Access Plans with Insights on Patient Support Programs: Whose Responsibility are They, and How Should They be Run?

NETWORKING LUNCH:
DELVE INTO INDUSTRY CONVERSATIONS

PANEL DISCUSSION: SWITCHING TO BIOSIMILARS

Incorporate the Latest Information on the Transition to Biosimilars into your Organizational Strategy

INDUSTRY EXPERT: INNOVATIVE NEW AGREEMENTS

Explore the New Types of Agreements and their Impact on Market Access Success

EXHIBITOR LOUNGE:
ATTEND VENDOR DEMOS & CONSULT INDUSTRY EXPERTS

PANEL DISCUSSION: BOOSTING DOMESTIC DRUG SUPPLY

Increasing the Resiliency of our Drug Supply and Supply Chain to Prevent and Mitigate Shortages

PANEL DISCUSSION: HOW DOES CANADA RANK?

A Comparative Analysis of the Canadian Market for Market Access and New Start-ups

CLOSING COMMENTS FROM YOUR HOST

CONFERENCE CONCLUDES